首頁 > 市場調查報告書 > 製藥

呼吸器

市場調查報告書

商品編碼

2148734

咽頭炎治療市場：依感染源、藥物類別、通路和地區分類

Pharyngitis Therapeutics Market, By Source of Infection, By Drug Class, By Distribution Channel, By Geography

出版日期: 2026年09月25日 | 出版商:

Coherent Market Insights | 英文 256 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，咽頭炎治療市場規模將達到 26 億美元，到 2033 年將達到 38 億美元。預計從 2026 年到 2033 年，該市場將以 4.8% 的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	26億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	4.80%	2033年市場規模預測：	38億美元

咽頭炎治療市場主要關注咽喉發炎和感染疾病的治療。醫療專業人員會為確診細菌咽頭炎患者開立抗生素，並建議使用止痛藥、抗發炎藥物、喉糖和症狀治療，以緩解疼痛、發燒和吞嚥困難。因咽喉痛症狀就診的門診量增加、診斷檢測手段的擴展以及人們對合理使用抗生素意識的提高，持續影響著醫院、診所和基層醫療機構對有效治療藥物的需求。

臨床醫生越來越重視準確診斷，以區分細菌性咽炎和性行為感染，咽頭炎選擇合適的治療方案。快速診斷檢測有助於醫護人員更快做出治療決策，並減少不必要的抗生素處方。製藥公司也正在研發改良配方，以緩解症狀、提高用藥便利性並增強患者依從性。兒童和成人呼吸道感染疾病、季節性疾病趨勢以及對高效門診服務的需求，持續推動對有效咽頭炎治療的需求。

市場動態

呼吸道感染疾病持續推基層醫療診所、醫院和藥局對咽頭炎藥物的需求。醫護人員擴大使用快速診斷檢測來區分細菌感染和性行為感染，感染疾病確定合適的治療方案。人們對合理使用抗生素的認知不斷提高，也促使臨床醫師僅在確診細菌感染疾病時才選擇性地開立抗生素。同時，患者仍需要止痛藥、抗發炎藥物、喉糖和症狀治療來緩解喉嚨痛、發燒和吞嚥困難等症狀。

診斷技術的進步為醫療專業人員更快地確定感染原因創造了新的機會。快速抗原檢測和分子診斷使臨床醫生能夠在初次就診時及時做出治療決策，避免不必要的治療延遲。製藥公司正在開發便利的製劑、聯合治療和患者易用的劑型，以提高患者的治療順從性。兒童護理需求的成長、季節性感染模式的出現以及門診服務覆蓋範圍的擴大，進一步加速了醫療專業人員採用有效且便捷的咽頭炎治療方案。

由於許多咽炎病例是由病毒引起的，導致抗生素治療需求下降，對症治療的依賴性增強，市場面臨許多挑戰。此外，抗生素抗藥性問題也促使臨床醫師進一步提高診斷準確性，並合理使用抗生素。市面上的藥物也面臨日益激烈的治療方案競爭。儘管有這些挑戰，醫療服務提供者仍優先考慮高效的治療方案，這些方案結合了精準診斷、症狀管理和標靶治療，這為製造商提供了新的機遇，使其能夠提供符合臨床需求和合理使用抗生素政策的產品。

本次調查的主要特點

該研究重點關注各個細分市場的潛在商機，並為參與咽頭炎治療市場的相關人員提供投資機會矩陣。
本研究深入分析了市場促進因素、限制因素、機會、治療方法、診斷技術進步、藥物創新、製劑、抗菌藥物的合理使用、疾病趨勢、區域展望以及主要市場參與企業採取的競爭策略。
本研究根據咽頭炎治療市場主要參與者的公司簡介、產品系列、最新進展、治療創新、研究活動、策略性舉措和市場定位，進行分析。
透過利用本報告中提出的見解，製藥公司、醫療保健提供者、投資者、診斷公司、研究機構、經銷商和經營團隊可以就藥物開發、治療策略、產品發布、技術投資、市場擴張、策略聯盟和治療創新做出明智的決策。
《咽頭炎治療市場》報告的目標受眾廣泛，包括投資者、製藥廠商、生物技術公司、醫療保健提供者、診斷設備製造商、藥局、經銷商、研究機構、技術開發商、新市場參與企業和金融相關人員。
相關人員可以透過「咽頭炎治療市場」報告中提出的分析框架、競爭基準、治療評估、治療分析、診斷評估、區域評估和市場評估矩陣做出明智的策略決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第8章競爭情勢

熱圖分析
市佔率分析
公司簡介
- Genentech Inc.
- Adamas Pharmaceutical Inc.
- PLIVA HRVATSKA doo
- Pfizer Inc.
- Valeant Pharmaceuticals International, Inc.
- Mylan NV
- GSK group of companies
- Teva Pharmaceutical Industries Ltd.
- AbbVie Inc.
分析師意見

第9章

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI2001

Pharyngitis Therapeutics Market is estimated to be valued at USD 2.6 Bn in 2026 and is expected to reach USD 3.8 Bn by 2033, growing at a compound annual growth rate (CAGR) of 4.8% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 2.6 Bn
Historical Data for:	2020 to 2024	Forecast Period:	2026 to 2033
Forecast Period 2026 to 2033 CAGR:	4.80%	2033 Value Projection:	USD 3.8 Bn

The pharyngitis therapeutics market focuses on treating throat inflammation and infections. Healthcare providers prescribe antibiotics for confirmed bacterial cases and recommend analgesics, anti-inflammatory medicines, lozenges, and supportive therapies to relieve pain, fever, and swallowing difficulties. Increasing outpatient consultations for sore throat symptoms, broader diagnostic testing, and growing awareness of responsible antimicrobial use continue to influence demand for effective treatment options across hospitals, clinics, and primary healthcare settings.

Clinicians increasingly prioritize accurate diagnosis to distinguish bacterial pharyngitis from viral infections and select appropriate treatments. Rapid diagnostic tests help healthcare providers make faster treatment decisions and limit unnecessary antibiotic prescriptions. Pharmaceutical companies are also developing improved formulations that enhance symptom relief, convenience, and treatment adherence. Pediatric and adult respiratory infections, seasonal disease patterns, and demand for efficient outpatient care continue to support the need for effective pharyngitis therapies.

Market Dynamics

Respiratory infections continue to drive demand for pharyngitis therapeutics across primary care clinics, hospitals, and pharmacies. Healthcare providers increasingly use rapid diagnostic tests to differentiate bacterial infections from viral cases and determine suitable treatment. Greater awareness of antimicrobial stewardship also encourages clinicians to prescribe antibiotics selectively for confirmed bacterial infections. Meanwhile, patients continue to seek analgesics, anti-inflammatory medicines, throat lozenges, and supportive therapies to relieve throat pain, fever, and swallowing difficulties.

Diagnostic advancements create new opportunities by helping healthcare providers identify infection causes more quickly. Rapid antigen tests and molecular diagnostic technologies enable clinicians to make timely treatment decisions during initial consultations and avoid unnecessary treatment delays. Pharmaceutical companies are developing convenient formulations, combination therapies, and patient-friendly dosage forms to improve treatment adherence. Growing pediatric healthcare demand, seasonal infection patterns, and wider access to outpatient services further encourage healthcare providers to adopt effective and convenient pharyngitis treatment options.

The market faces challenges because viruses cause many pharyngitis cases, reducing the need for antibiotic therapy and increasing reliance on supportive care. Antimicrobial resistance further encourages clinicians to improve diagnosis and practice responsible antibiotic prescribing. Over-the-counter symptom-relief products also intensify competition among therapeutic alternatives. Despite these challenges, healthcare providers continue to prioritize efficient treatment pathways that combine accurate diagnosis, symptom management, and targeted therapy, creating opportunities for manufacturers that align their products with clinical requirements and antimicrobial stewardship.

Key Features of the Study

It highlights potential revenue opportunities across various market segments and provides investment opportunity matrices for stakeholders involved in the Pharyngitis Therapeutics Market.
This study offers key insights into market drivers, restraints, opportunities, treatment approaches, diagnostic advancements, pharmaceutical innovations, drug formulations, antimicrobial stewardship, disease patterns, regional outlook, and competitive strategies adopted by leading market participants.
It profiles key players in the Pharyngitis Therapeutics Market based on company overview, product portfolio, recent developments, therapeutic innovations, research activities, strategic initiatives, and market positioning.
Key companies covered as part of this study include Genentech Inc., Adamas Pharmaceutical Inc., PLIVA HRVATSKA d.o.o., Pfizer Inc., Valeant Pharmaceuticals International, Inc., Mylan N.V., GSK group of companies, Teva Pharmaceutical Industries Ltd., and AbbVie Inc.
Insights from this report enable pharmaceutical companies, healthcare providers, investors, diagnostic companies, research organizations, distributors, and management teams to make informed decisions regarding drug development, treatment strategies, product launches, technology investments, market expansion, strategic collaborations, and therapeutic innovation.
The Pharyngitis Therapeutics Market report serves a wide range of stakeholders, including investors, pharmaceutical manufacturers, biotechnology companies, healthcare providers, diagnostic companies, pharmacies, distributors, research organizations, technology developers, new market entrants, and financial analysts.
Stakeholders can make well-informed strategic decisions through the analytical frameworks, competitive benchmarking, therapeutic assessment, treatment analysis, diagnostic evaluation, regional assessment, and market evaluation matrices presented in the Pharyngitis Therapeutics Market report.

Market Segmentation

By Source of Infection (Revenue, USD Bn, 2021-2033)
- Viral
- Bacterial
By Drug Class (Revenue, USD Bn, 2021-2033)
- Antiviral Drugs
- Antibacterial Drugs
- Anti-inflammatory Drugs
- Topical Anesthetics Drugs
By Distribution Channel (Revenue, USD Bn, 2021-2033)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Region (Revenue, USD Bn, 2021-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
Key Players
- Genentech Inc.
- Adamas Pharmaceutical Inc.
- PLIVA HRVATSKA d.o.o.
- Pfizer Inc.
- Valeant Pharmaceuticals International, Inc.
- Mylan N.V.
- GSK group of companies
- Teva Pharmaceutical Industries Ltd.
- AbbVie Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Source of Infection
- Market Snapshot, By Drug Class
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Product Approval
Collaboration/Merge/Acquisition
Regulatory Landscape
PEST Analysis
Porter's Five Forces Analysis
Epidemiology
Robust Pipeline Analysis

4. Global Pharyngitis Therapeutics Market, By Source of Infection, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Viral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Bacterial
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

5. Global Pharyngitis Therapeutics Market, By Drug Class, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Antiviral Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Antibacterial Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Anti-inflammatory Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Topical Anesthetics Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

6. Global Pharyngitis Therapeutics Market, By Distribution Channel, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

7. Global Pharyngitis Therapeutics Market, By Region, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Source of Infection, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Source of Infection, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Source of Infection, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Source of Infection, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Source of Infection, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Source of Infection, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Billion)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Heat Map Analysis
Market Share Analysis
Company Profile
- Genentech Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Adamas Pharmaceutical Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
- Market Strategies
- PLIVA HRVATSKA d.o.o.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Pfizer Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Valeant Pharmaceuticals International, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Mylan N.V.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- GSK group of companies
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Teva Pharmaceutical Industries Ltd.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- AbbVie Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
Analyst Views